From January 1, 2024 to March 31, 2024, the company has repurchased 2,966,000 shares, representing 0.2% for CNY 38.41 million. With this, the company has completed the repurchase of 7,023,100 shares, representing 0.48% for CNY 99.99 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.75 CNY | +3.97% | +6.62% | +14.18% |
Apr. 29 | Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 24 | Huahai Pharmaceutical Gets Approval to Market Busulfan Injection | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.18% | 3.41B | |
+34.00% | 704B | |
+25.45% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+14.99% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.